Categories: Clinical TrialNews

Albireo to Participate in H.C. Wainwright 3rd Annual Hepatitis B Virus (HBV) Conference

BOSTON, Oct. 12, 2022 (GLOBE NEWSWIRE) — Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced participation in the Wainwright 3rd Annual Hepatitis B Virus (HBV) Conference on October 18, 2022. Albireo will be presenting and will host investor meetings.

A replay of the webcast will be available on-demand on the Albireo Investors page: ir.albireopharma.com.

About Albireo  

Albireo Pharma is a rare disease company focused on the development of novel bile acid modulators to treat pediatric and adult liver diseases. Albireo’s lead product, Bylvay, was approved by the U.S. FDA as the first drug for the treatment of pruritus in all types of progressive familial intrahepatic cholestasis (PFIC), and it is also being developed to treat other rare pediatric cholestatic liver diseases with a completed Phase 3 trial in Alagille syndrome (ALGS), an ongoing Phase 3 study in biliary atresia, as well as Open-label Extension (OLE) studies for PFIC and ALGS. In Europe, Bylvay is reimbursed for the treatment of PFIC in Germany, England, Wales & Northern Ireland, Scotland, Italy, and Belgium. The Company has also completed a Phase 1 clinical trial for A3907 to advance development in adult cholestatic liver disease, with IND-enabling studies progressing with A2342 for viral and cholestatic liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. For more information on Albireo, please visit www.albireopharma.com.   

Media Contacts:
Colleen Alabiso, 857-356-3905, colleen.alabiso@albireopharma.com
Lance Buckley, 917-439-2241, lbuckley@lippetaylor.com

Investor Contact:
Hans Vitzthum, LifeSci Advisors, LLC., 617-430-7578

Staff

Recent Posts

Semler Scientific® Announces Additional Bitcoin Purchases

SANTA CLARA, Calif., June 6, 2024 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a pioneer…

2 hours ago

Orange County Soccer Club Taps GENEFIT for Comprehensive Genes-Based Performance and Recovery Insights

The sports-tech innovator powered by 3X4 Genetics will work closely with OCSC coaching, training, and…

2 hours ago

PHTI Study Confirms Positive Clinical and Economic Outcomes for Physical Therapist-Guided Virtual MSK Solutions, Including RecoveryOne

WALNUT CREEK, Calif., June 6, 2024 /PRNewswire/ -- RecoveryOne, a leading virtual musculoskeletal (MSK) care provider…

2 hours ago

Notification of Data Security Incident Best Health Physical Therapy, LLC

GROTON, Conn., June 6, 2024 /PRNewswire/ -- On February 26, 2024, Best Health Physical Therapy,…

2 hours ago

NextSense Honored as World Economic Forum Technology Pioneer

MOUNTAIN VIEW, Calif., June 6, 2024 /PRNewswire/ -- NextSense is proud to announce that it…

2 hours ago